NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

FORT WORTH, Texas–(BUSINESS WIRE)–Patent covers intratumoral delivery of certain LSAM investigational drugs with systemic Immune Checkpoint Inhibitors.
Click here to view original post